Software-Guided heart valve implant aims to boost precision in aortic stenosis
NCT ID NCT07696182
First seen Jul 10, 2026 · Last updated Jul 10, 2026
Summary
This clinical trial is testing a new heart valve replacement system called Encantor, which uses software to guide placement of the valve. The study includes 150 adults with severe aortic stenosis who are candidates for a minimally invasive procedure. Researchers will track how many patients survive without having a stroke one year after the procedure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Encantor TAVI System (transcatheter aortic valve replacement device)
- What this could lead to
- If successful, this software-guided approach could make heart valve replacement safer and more precise for people with severe aortic stenosis.
- What could go wrong
- This is an early-stage study with only 150 participants, so results may not apply to everyone. Risks include complications from the procedure itself, such as stroke or death.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE NATIVE CALCIFIC AORTIC STENOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••